475PUpdated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. (23rd October 2018) - Nakamura, M; Takashima, A; Denda, T; Gamoh, M; Iwanaga, I; Komatsu, Y; Takahashi, M; Ohori, H; Sekikawa, T; Tsuda, M; Kobayashi, Y; Miyamoto, Y; et al.